Side skin reactions of multikinase inhibitors in treatment of thyroid cancer

Dermal toxicity of anti-cancer drugs apparent in patients with thyroid cancer. This side effect appears, in particular, in relation to increased administration of targeted anti-cancer treatment, especially tyrosinkinase inhibitors, towards various receptors of growth factors which are applied in the ethiopathogenesis of a tumor cell. Our article focuses on the dermatotoxity, designated also as skin reaction, which most frequently occurs in patients treated by tyrosinkinase inhibitors – sorafenib, vandetonib, cabozantinib and lenvantinib. High prevalence of dermatotoxity, reported by patients, treated with these drugs underscores the need for greater understanding of the pathogenesis and management of this syndrome.

dermatotoxicity, side effects, multikinase inhibitors, sorafenib, vandetanib, cabozantinib, lenvantinib

1. Thomas L., Lai S.Y., Dong W. et al. Sorafenib in metastatic thyroid cancer: a systematic review. Oncologist 2014;19(3):251–8. DOI: 10.1634/theoncologist.2013-0362.

2. Strumberg D., Awada A., Hirte H. et al. Pooled safety analysis of BAY 43-9006 (sorafenib) monotherapy in patients with advanced solid tumours: is rash associated with treatment outcome? Eur J Cancer 2006;42(4):548–56. DOI: 10.1016/j.ejca.2005.11.014.

3. Lam E.T., Ringle M.D., Kloos R.T. et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28(14):2323–30. DOI: 10.1200/JCO.2009.25.0068.

4. Ratain M.J., Eisen T., Stadler W.M. et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2006;24(16):2505–12. DOI: 10.1200/JCO.2005.03.6723.

5. Escudier B., Eisen T., Stradler W.M. et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125–34. DOI: 10.1056/NEJMoa060655.

6. Wells S.A. Jr, Robinson B.G., Gagel R.F. et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30(2):134–41. DOI: 10.1200/JCO.2011.35.5040.

7. Schlumberger M., Elisei R., Müller S. et al. Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma. Ann Oncol 2017;28(11):2813–9. DOI: 10.1093/annonc/mdx479.

8. Elisei R., Schlumberger M.J., Müller S.P. et al. Cabozantinib in progressive medullary thyroid cancer [published correction appears in J Clin Oncol. 2014;32(17):1864]. J Clin Oncol 2013;31(29):3639–46. DOI: 10.1200/JCO.2012.48.4659.

9. Milling R.V., Grimm D., Krüger M. et al. Pazopanib, cabozantinib, and vandetanib in the treatment of progressive medullary thyroid cancer with a special focus on the adverse effects on hypertension. Int J Mol Sci 2018;19(10):3258. DOI: 10.3390/ijms19103258.

10. Schlumberger M., Tahara M., Wirth L.J. et al. Lenvatinib versus placebo in radioiodine-refractory thyroi cancer. N Engl J Med 2015;372:621–30. DOI: 10.1056/NEJMoa1406470.

11. Tahara M., Kiyota N., Yamazaki T. et al. Lenvatinib for anaplastic thyroid cancer. Front Oncol 2017;7:25. DOI: 10.3389/fonc.2017.00025.

12. Бородавина Е.В., Исаев П.А., Шуринов А.Ю. и др. Эффективность и переносимость ленватиниба при радиойодрезистентном дифференцированном раке щитовидной железы по результатам многоцентрового наблюдательного исследования в Российской Федерации. Опухоли головы и шеи 2020;10(1):65–72. DOI: 10.17650/2222-1468-2020- 10-1-65-72.

13. Lee W.J., Lee J.L., Chang S.E. et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol 2009;161(5):1045–51. DOI: 10.1111/j.1365-2133.2009.09290.x.

14. McLellan B., Kerr H. Cutaneous toxicities of the multikinase inhibitors sorafenib and sunitinib. Dermatol Ther 2011;24:396–400. DOI: 10.1111/j.1529-8019.2011.01435.x.

15. Chanprapaph K., Rutnin S., Vachiramon V. Multikinase inhibitorinduced handfoot skin reaction: a review of clinical presentation, pathogenesis, and management. Am J Clin Dermatol 2016;17(4):387–402. DOI: 10.1007/s40257-016-0197-1.

16. Cabanillas M.E., Waguespack S.G., Bronstein Y. et al. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: The M.D. Anderson experience. J Clin Endocrinol Metab 2010;95:2588–95. DOI: 10.1210/jc.2009-1923.

17. Kloos R.T., Ringel M.D., Knopp M.V. et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27:1675–84. DOI: 10.1200/JCO.2008.18.2717.

18. Снеговой А.В., Болотина Л.В., Горбунова В.А. и соавт. Практические рекомендации по коррекции дерматологических реакций у пациентов, получающих терапию ингибиторами EGFR. Злокачественные опухоли 2016;(4, спецвыпуск 2):428–33. [Snegovoy A.V., Bolotina L.V., Gorbunova V.A. et al. Practical recommendations for the correction of dermatological reactions in patients receiving therapy with EGFR inhibitors. Zlokachestvennye opukholi = Malignant tumors 2016;(4 Special Issue 2):428–33. (In Russ.)]. DOI: 10.18027/ 2224-5057-2016-4s2-428-433.